HB1426 creates a new “clinical research pharmacy” permit within the Maryland State Board of Pharmacy and sets out the conditions under which a pharmacy may operate under that permit. To qualify, the pharmacy must be used exclusively for scientific research under institutional review board protocols that meet FDA guidelines, must dispense only as incident to the research being conducted, must not be open to the general public for retail pharmacy services, and must comply with security, storage, and other standards adopted by regulation. The bill also requires the Board to establish application, inspection, suspension, and revocation rules for these pharmacies.
The bill further addresses ownership and professional oversight. It allows a health care provider to hold an ownership interest in a clinical research pharmacy under specified conditions, including that a licensed pharmacist be on-site during all operating hours and retain responsibility for compounding, dispensing, and pharmacy oversight. It also states that ownership alone cannot be the sole basis for discipline against an unlicensed owner, while preserving the authority of health occupations boards to investigate unauthorized practice or other violations. In addition, the bill amends the definition of the practice of medicine to exclude certain investigational or experimental treatments and clinical trials conducted by corporations or other legal entities, so long as those activities follow approved protocols, use licensed individuals for medical decision-making, and do not amount to general medical practice or ordinary patient care outside the trial.
The bill’s impact on state law is to create a new regulatory category for research-focused pharmacies and to clarify the boundary between regulated medical practice and clinical research. It amends the Health Occupations Article to add new definitions, authorize the Board of Pharmacy to issue permits, and limit when ownership interests in these pharmacies trigger licensing concerns. It also narrows the reach of the medical practice definition in Title 14 for certain clinical trial activities, which may reduce legal uncertainty for research institutions, pharmaceutical research operations, and health care providers involved in clinical studies.
The overall sentiment appears broadly favorable. The House passed the bill overwhelmingly on third reading, 125-5, and the committee report was favorable with amendments, suggesting strong support for the bill’s policy goals. The available record does not show recorded committee debate, but the vote margin indicates little opposition in the House.
The main points of potential contention are the ownership provisions and the carve-out from the practice of medicine definition. Concerns could center on whether allowing health care providers to own interests in research pharmacies creates conflicts of interest, whether the on-site pharmacist requirement is sufficient to protect patient safety, and whether the clinical-trial exemption could be used too broadly by entities seeking to avoid medical licensing rules. The bill responds to those concerns by limiting the pharmacies to research-only operations, requiring licensed pharmacist oversight, and preserving board enforcement authority over unauthorized practice.
HB1426 amends the Maryland Health Occupations Article to establish a new clinical research pharmacy permit, define clinical research pharmacy and related terms, and authorize the State Board of Pharmacy to regulate, inspect, suspend, and revoke these permits. It also creates a limited ownership framework allowing certain health care providers to hold ownership interests in such pharmacies under strict operational and oversight conditions. Separately, it amends the definition of “practice medicine” to exclude qualifying investigational or experimental treatments and clinical trials conducted by corporations or other legal entities, thereby clarifying that some research activities do not require a medical license when they are conducted under approved protocols and within the scope of clinical research.
The bill appears to have received generally favorable treatment in the House. It was reported out of committee favorably with amendments and passed third reading by a wide margin, 125-5, indicating strong bipartisan or near-bipartisan support. The absence of recorded committee transcript discussion limits insight into detailed arguments, but the voting history suggests the chamber viewed the bill as a targeted regulatory clarification rather than a controversial policy shift.
Potential contention lies in the bill’s treatment of ownership and professional boundaries. Critics could question whether allowing health care providers to own clinical research pharmacies creates conflicts of interest or referral incentives, even though the bill prohibits remuneration for referrals and requires pharmacist independence. Another possible concern is the exemption from the practice of medicine definition for certain clinical trials, which may raise questions about oversight, patient protection, and whether non-licensed entities could indirectly engage in medical activity. Supporters likely view these provisions as necessary to facilitate legitimate research while preserving board oversight and limiting the exemption to tightly controlled trial settings.